Vivos Therapeutics develops treatments for patients with dentofacial abnormalities, mild-to-moderate obstructive sleep apnea and snoring.
The deal involves the sale of 980,393 shares of its common stock for $4.08 per share, according to an Oct. 31 news release.
The deal is expected to close Nov. 2.
Vivos Therapeutics said it intends to use proceeds from the deal for general corporate purposes.
